• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝脏半乳糖凝集素-3 阳性细胞的数量与儿童非酒精性脂肪性肝病的严重程度呈双重相关。

The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children.

机构信息

Federal University of Rio de Janeiro, Institute of Biomedical Sciences, 21941-902 Rio de Janeiro, Brazil.

Molecular Genetics of Complex Phenotypes Research Unit, Bambino Gesù Hospital, IRCCS, 00146 Rome, Italy.

出版信息

Int J Mol Sci. 2019 Jul 14;20(14):3460. doi: 10.3390/ijms20143460.

DOI:10.3390/ijms20143460
PMID:31337151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6679049/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a complex disease ranging from steatosis to non-alcoholic steatohepatitis (NASH). Galectin-3 (Gal-3), which is a β-galactoside binding protein, has been associated with liver fibrosis, but its role in NAFLD remains elusive. We investigated the expression of Gal-3 in liver resident cells and its potential association with liver damage in 40 children with biopsy-proven NAFLD. We found that several liver cells expressed Gal-3. The number of total Gal-3 positive cells decreased with the severity of disease and the cells were correlated with the presence of steatosis and the diagnosis of NASH. CD68 macrophages expressed Gal-3 but the number CD68/Gal-3 positive cells was significantly reduced in patients diagnosed with steatosis and NASH. Triple CD68/CD206/Gal-3, which represented the subpopulation of M2 macrophages, were mainly present in patients without NASH, and clearly reduced in patients with steatosis and NASH. On the contrary, the number of α-smooth muscle actin (SMA)/Gal-3 positive cells increased with the severity of fibrosis in children with NAFLD. Our data demonstrated that the number of Gal-3 positive cells was associated with tissue damage in different ways, which suggests a dual role of this protein in the pathogenesis of pediatric NAFLD, even if the role of Gal-3 deserves further studies.

摘要

非酒精性脂肪性肝病(NAFLD)是一种复杂的疾病,其范围从脂肪变性到非酒精性脂肪性肝炎(NASH)。半乳糖凝集素-3(Gal-3)是一种β-半乳糖苷结合蛋白,与肝纤维化有关,但它在 NAFLD 中的作用仍不清楚。我们研究了 Gal-3 在肝固有细胞中的表达及其与 40 例经活检证实的 NAFLD 儿童肝损伤的潜在相关性。我们发现几种肝细胞表达 Gal-3。总 Gal-3 阳性细胞的数量随着疾病的严重程度而减少,并且这些细胞与脂肪变性的存在和 NASH 的诊断相关。CD68 巨噬细胞表达 Gal-3,但在诊断为脂肪变性和 NASH 的患者中,CD68/Gal-3 阳性细胞的数量明显减少。CD68/CD206/Gal-3 的三阳性细胞,代表 M2 巨噬细胞的亚群,主要存在于无 NASH 的患者中,在脂肪变性和 NASH 的患者中明显减少。相反,α-平滑肌肌动蛋白(SMA)/Gal-3 阳性细胞的数量随着儿童 NAFLD 纤维化的严重程度而增加。我们的数据表明,Gal-3 阳性细胞的数量以不同的方式与组织损伤相关,这表明该蛋白在小儿 NAFLD 发病机制中具有双重作用,尽管 Gal-3 的作用值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/629a73ab54d4/ijms-20-03460-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/c8d53fdde78d/ijms-20-03460-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/732d4b39c3ac/ijms-20-03460-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/0a77b5366b1a/ijms-20-03460-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/75530457c23e/ijms-20-03460-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/629a73ab54d4/ijms-20-03460-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/c8d53fdde78d/ijms-20-03460-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/732d4b39c3ac/ijms-20-03460-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/0a77b5366b1a/ijms-20-03460-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/75530457c23e/ijms-20-03460-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab5/6679049/629a73ab54d4/ijms-20-03460-g005.jpg

相似文献

1
The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children.肝脏半乳糖凝集素-3 阳性细胞的数量与儿童非酒精性脂肪性肝病的严重程度呈双重相关。
Int J Mol Sci. 2019 Jul 14;20(14):3460. doi: 10.3390/ijms20143460.
2
Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.半乳糖凝集素-3与白细胞介素-33/ST2轴在饮食诱导的脂肪性肝炎中的作用及相互作用
World J Gastroenterol. 2016 Nov 28;22(44):9706-9717. doi: 10.3748/wjg.v22.i44.9706.
3
CD44 is a key player in non-alcoholic steatohepatitis.CD44 是非酒精性脂肪性肝炎的关键参与者。
J Hepatol. 2017 Aug;67(2):328-338. doi: 10.1016/j.jhep.2017.03.003. Epub 2017 Mar 16.
4
M1-/M2-macrophage polarization in pseudolobules consisting of adipohilin-rich hepatocytes in thioacetamide (TAA)-induced rat hepatic cirrhosis.硫代乙酰胺(TAA)诱导的大鼠肝硬化中,由富含脂肪滴结合蛋白的肝细胞组成的假小叶内M1型/M2型巨噬细胞极化
Exp Mol Pathol. 2016 Aug;101(1):133-42. doi: 10.1016/j.yexmp.2016.07.005. Epub 2016 Jul 21.
5
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.非酒精性脂肪性肝病——组织学评分系统:一项大型队列单中心评估研究。
APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742.
6
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.巨噬细胞活化标志物 sCD163 与非酒精性脂肪性肝病患者的形态学疾病分期相关。
Liver Int. 2016 Oct;36(10):1549-57. doi: 10.1111/liv.13150. Epub 2016 May 12.
7
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中脂肪组织胰岛素抵抗与肝巨噬细胞的串扰。
J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031. Epub 2019 Jul 10.
8
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.使用配对活检评估非酒精性脂肪性肝病从脂肪变性进展为纤维性脂肪性肝炎的证据:对预后和临床管理的影响。
J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1.
9
Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.靶向分析三个激素系统,鉴定与 NAFLD 的存在和严重程度相关的分子。
J Clin Endocrinol Metab. 2020 Mar 1;105(3):e390-400. doi: 10.1210/clinem/dgz172.
10
Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.接受减肥手术的病态肥胖患者中巨噬细胞活化标志物可溶性CD163与非酒精性脂肪性肝病
J Gastroenterol Hepatol. 2015 Aug;30(8):1293-300. doi: 10.1111/jgh.12943.

引用本文的文献

1
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝炎的当前治疗现状
Int J Mol Sci. 2025 Feb 19;26(4):1778. doi: 10.3390/ijms26041778.
2
Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study.一项基于社区的横断面研究中半乳糖凝集素-3与肝脂肪变性的关联。
Ther Adv Chronic Dis. 2024 Nov 30;15:20406223241302719. doi: 10.1177/20406223241302719. eCollection 2024.
3
Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.

本文引用的文献

1
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.巨噬细胞在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159. doi: 10.1038/s41575-018-0082-x.
2
The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.半乳糖凝集素-3在调节肿瘤生长及肿瘤微环境内免疫抑制中的作用。
Oncoimmunology. 2018 Feb 20;7(6):e1434467. doi: 10.1080/2162402X.2018.1434467. eCollection 2018.
3
Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).
半乳糖凝集素-3 与代谢相关脂肪性肝病肝纤维化严重程度的关系。
Protein Pept Lett. 2024;31(4):290-304. doi: 10.2174/0109298665301698240404061300.
4
Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis.半乳糖凝集素-3抑制作为非酒精性脂肪性肝炎肝纤维化的潜在治疗靶点。
World J Hepatol. 2023 Feb 27;15(2):201-207. doi: 10.4254/wjh.v15.i2.201.
5
Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling.半乳糖凝集素-3 通过抑制细胞焦亡信号而不是坏死信号,在 ACLF 中关键性地介导了 M2 样巨噬细胞发挥的肝保护作用。
Cell Death Dis. 2022 Sep 8;13(9):775. doi: 10.1038/s41419-022-05181-1.
6
Untangling the Extracellular Matrix of Idiopathic Epiretinal Membrane: A Path Winding among Structure, Interactomics and Translational Medicine.解开特发性眼内视网膜膜细胞外基质的谜团:结构、相互作用组学和转化医学之间的曲折路径。
Cells. 2022 Aug 15;11(16):2531. doi: 10.3390/cells11162531.
7
Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model.肝半乳糖凝集素-3与新猪模型非酒精性脂肪性肝炎中脂滴面积相关。
Sci Rep. 2022 Jan 19;12(1):1024. doi: 10.1038/s41598-022-04971-z.
8
ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study.ASC、IL-18 和半乳糖凝集素-3 作为非酒精性脂肪性肝炎的生物标志物:概念验证研究。
Int J Mol Sci. 2020 Nov 13;21(22):8580. doi: 10.3390/ijms21228580.
9
Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms.小儿非酒精性脂肪肝疾病:营养起源与潜在分子机制。
Nutrients. 2020 Oct 16;12(10):3166. doi: 10.3390/nu12103166.
10
Activation of Galectin-3 (LGALS3) Transcription by Injurious Stimuli in the Liver Is Commonly Mediated by BRG1.肝脏中损伤性刺激对半乳糖凝集素-3(LGALS3)转录的激活通常由BRG1介导。
Front Cell Dev Biol. 2019 Nov 26;7:310. doi: 10.3389/fcell.2019.00310. eCollection 2019.
半乳糖凝集素-3 作为一种新型疾病诊断生物标志物和治疗靶点的研究进展(综述)。
Int J Mol Med. 2018 Feb;41(2):599-614. doi: 10.3892/ijmm.2017.3311. Epub 2017 Dec 5.
4
Pre-natal and post-natal environment monitoring to prevent non-alcoholic fatty liver disease development.产前和产后环境监测以预防非酒精性脂肪性肝病的发生。
J Hepatol. 2017 Sep;67(3):451-453. doi: 10.1016/j.jhep.2017.04.016. Epub 2017 Jun 12.
5
The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications.组织巨噬细胞介导的炎症在非酒精性脂肪性肝病发病机制中的作用及其临床意义
Mediators Inflamm. 2017;2017:8162421. doi: 10.1155/2017/8162421. Epub 2017 Jan 1.
6
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.随机临床研究:GR-MD-02,一种半乳糖凝集素-3 抑制剂,与安慰剂在非酒精性脂肪性肝炎伴晚期纤维化患者中的比较。
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1183-1198. doi: 10.1111/apt.13816. Epub 2016 Oct 24.
7
NAFLD and liver transplantation: Current burden and expected challenges.非酒精性脂肪性肝病与肝移植:当前负担及预期挑战
J Hepatol. 2016 Dec;65(6):1245-1257. doi: 10.1016/j.jhep.2016.07.033. Epub 2016 Jul 30.
8
Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway.儿童非酒精性脂肪性肝病(NAFLD)中的巨噬细胞活化通过Wnt3a途径与肝祖细胞反应相关。
PLoS One. 2016 Jun 16;11(6):e0157246. doi: 10.1371/journal.pone.0157246. eCollection 2016.
9
Nonalcoholic fatty liver disease.非酒精性脂肪性肝病。
Nat Rev Dis Primers. 2015 Dec 17;1:15080. doi: 10.1038/nrdp.2015.80.
10
Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病儿童与成人患者的表型及治疗方法比较
Gastroenterology. 2016 Jun;150(8):1798-810. doi: 10.1053/j.gastro.2016.03.009. Epub 2016 Mar 19.